Patients with low TMB exhibited improved clinical outcomes, while distinct mutational profiles between high-TMB and low-TMB groups (e.g., VHL mutations in high TMB vs. DNAH9 in low TMB) emphasized the genomic heterogeneity of ccRCC and the need for tailored therapies. The gene discussed is DNAH9; the disease is nonpapillary renal cell carcinoma.